JD Health International Inc. (6618.HK) Stock Analysis

JD Health International is China’s largest online healthcare platform, offering a comprehensive 'Internet + Healthcare' ecosystem through its leading retail pharmacy and digital healthcare services. With a circa-40% share in the healthcare e-commerce market and benefiting from JD.com’s infrastructure and brand, the company demonstrates strong revenue growth (24.5% YoY in H1 2025), surging profits (up 94% in 2024), and expanding gross margins, fueled by high-margin, tech-driven service growth and omnichannel integration. Strategic AI investments with its proprietary 'AI Jingyi' further enhance services and operational leverage. While poised to capitalize on demographic and government-policy-driven digital health sector growth, JD Health faces unpredictable regulatory risks, fierce competition, and ongoing capital allocation headwinds.